ProfileGDS5678 / 1454922_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 74% 74% 73% 77% 75% 74% 75% 75% 77% 74% 77% 74% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8734775
GSM967853U87-EV human glioblastoma xenograft - Control 24.9175374
GSM967854U87-EV human glioblastoma xenograft - Control 34.8248774
GSM967855U87-EV human glioblastoma xenograft - Control 44.8672673
GSM967856U87-EV human glioblastoma xenograft - Control 55.3279277
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8754675
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7537174
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9737975
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9399975
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.3267377
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.877174
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2428777
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.8083174
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.8423174